Clinical implementation of bempedoic acid in blood lipid management: Real-world data from an Italian lipid clinic
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.09.033 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Chiara Pavanello und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dyslipidemia Center, Niguarda Hospital, Milan, Italy (Drs Pavanello, Mombelli, Mr Castiglione, Drs Santolamazza, Sirtori, and Alberti). Electronic ad…. Hauptthemen laut MEDLINE: Dicarboxylic Acids, Fatty Acids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Ministero dell’Istruzione, dell’Università e della Ricerca.
Abstract (Originalsprache)
BACKGROUND: Bempedoic acid (BA), an ATP citrate lyase inhibitor, is approved for low-density lipoprotein (LDL)-cholesterol reduction and is well tolerated, especially in statin-intolerant patients. Real-world evidence, particularly from Europe, remains limited. OBJECTIVE: To assess real-world effectiveness, safety, and predictors of LDL-cholesterol target achievement with BA in Italian patients. METHODS: We conducted a retrospective observational study of 160 patients treated with BA at a lipid clinic in Milan, Italy. Patients were followed for 12 months. LDL-cholesterol levels, laboratory parameters, clinical events, and adverse effects were collected. Effectiveness was assessed as percentage change in LDL-cholesterol from baseline. Predictors of LDL-cholesterol target achievement were identified using multivariable logistic regression. RESULTS: BA significantly reduced LDL-cholesterol from 116.1 ± 49.3 to 78.5 ± 36.0 mg/dL (-26.1%, P < .05). The majority of patients (60.8%) reached European Society of Cardiology/European Atherosclerosis Society LDL-cholesterol goals (≤55 mg/dL). LDL-cholesterol reduction was greater in statin-intolerant patients (-29.0% vs -21.0%) and smaller in those with familial hypercholesterolemia (FH) (-18.0% vs -29.2%). Independent predictors of target non-achievement were FH (odds ratio [OR] 0.045, 95% CI 0.004-0.523, P = .013), while concomitant proprotein convertase subtilisin kexin type 9 inhibitor use predicted success (OR 31.82, 95% CI 2.57-394.17, P = .007). Among 69 patients not achieving LDL-cholesterol targets, 84% were on maximally tolerated lipid-lowering therapy (LLT), 67% were statin-intolerant, and 11 had FH. Safety analysis showed good tolerability; 4.0% developed hyperuricemia, and only 2 atherosclerotic cardiovascular disease events occurred during follow-up. CONCLUSION: BA was effective and well tolerated in this high-risk cohort, including statin-intolerant and FH patients. Beyond its initial indication, BA now represents a valuable therapeutic option to optimize LDL-cholesterol lowering in patients who remain above target despite standard LLT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dyslipidemia Center, Niguarda Hospital, Milan, Italy (Drs Pavanello, Mombelli, Mr Castiglione, Drs Santolamazza, Sirtori, and Alberti). Electronic address: chiara.pavanello@unimi.it.
- E. Grossi Paoletti Center, Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy (Cincotto, Drs Calabresi and Sirtori).
- Dyslipidemia Center, Niguarda Hospital, Milan, Italy (Drs Pavanello, Mombelli, Mr Castiglione, Drs Santolamazza, Sirtori, and Alberti).
- E. Grossi Paoletti Center, Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy (Cincotto, Drs Calabresi and Sirtori); Dyslipidemia Center, Niguarda Hospital, Milan, Italy (Drs Pava…
Förderung
- Pfizer
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Pavanello, C., Cincotto, G., Mombelli, G. G., Castiglione, S., Santolamazza, C., Calabresi, L., Sirtori, C. R., & Alberti, A. (2025). Clinical implementation of bempedoic acid in blood lipid management: Real-world data from an Italian lipid clinic. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.09.033
Vancouver
Pavanello C, Cincotto G, Mombelli GG, Castiglione S, Santolamazza C, Calabresi L, et al. Clinical implementation of bempedoic acid in blood lipid management: Real-world data from an Italian lipid clinic. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.09.033
BibTeX
@article{Pavanello2025,
author = {Pavanello, Chiara and Cincotto, Giulia and Mombelli, Giuliana Germana and Castiglione, Sofia and Santolamazza, Caterina and Calabresi, Laura and Sirtori, Cesare Riccardo and Alberti, Antonia},
title = {Clinical implementation of bempedoic acid in blood lipid management: Real-world data from an Italian lipid clinic},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.09.033}
}
EUVIMED